Nitroalkene inhibition of pro-inflammatory macrophage effector function via modulation of signaling metabolite levels
The current data provide additional perspective on the actions of this small-molecule electrophile, which is currently in a Phase 2 clinical trial for the treatment of obesity-related chronic pulmonary inflammation and associated airway dysfunction.
Authors
- Karina C. Lockwood
- Bruce Α. Freeman (ORCID: https://orcid.org/0000-0002-2028-8369)
- Crystal Uvalle
- Emily Stevenson (ORCID: https://orcid.org/0000-0003-1329-8734)
- Tomeka Suber (ORCID: https://orcid.org/0000-0002-7062-0278)
- Gregory J. Buchan (ORCID: https://orcid.org/0000-0002-5592-7888)
- Stacy G. Wendell (ORCID: https://orcid.org/0000-0001-9083-6933)
- Allison M. Manuel (ORCID: https://orcid.org/0000-0003-2853-7005)
- James P. O’Brien (ORCID: https://orcid.org/0000-0003-2784-6906)
- Steven J. Mullett (ORCID: https://orcid.org/0009-0005-6971-9288)
Institutions
- University of Pittsburgh (US)
Publication Details
- Journal
- Frontiers in Physiology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.3389/fphys.2025.1426102
- Primary Topic
- Eicosanoids and Hypertension Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00